2566 — Hangzhou Jiuyuan Genetic Biopharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- HK$1.45bn
- HK$1.00bn
- CNY1.37bn
- 73
- 68
- 36
- 65
Annual income statement for Hangzhou Jiuyuan Genetic Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 1,307 | 1,125 | 1,287 | 1,369 |
| Cost of Revenue | ||||
| Gross Profit | 950 | 854 | 991 | 1,082 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 1,170 | 1,065 | 1,143 | 1,193 |
| Operating Profit | 137 | 60.5 | 144 | 176 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | 128 | 51.4 | 135 | 169 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 119 | 59.9 | 120 | 139 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 119 | 59.9 | 120 | 139 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 119 | 59.9 | 120 | 139 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.488 | 0.245 | 0.53 | 0.668 |
| Dividends per Share |